AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
Circle Pharma and Verismo feature in coveted sessions.
Projects from Chia Tai and Kestrel enter phase 1, along with a bispecific Kelun ADC.
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
